摘要
目的:探究雷公藤多苷治疗紫癜性肾炎患儿的疗效和安全性。方法:选取2018年2月至2019年1月连云港市第二人民医院儿科收治的紫癜性肾炎患儿96例作为研究对象,随机分为观察组和对照组,每组48例。对照组采用常规治疗,观察组在对照组基础上采用雷公藤多苷片进行治疗,1 mg/(kg·d),分3次于饭后服用。2组患儿均持续治疗5 d。比较2组临床疗效、4-1 BB/4-1 BBL、免疫功能、炎性反应因子、安全性。结果:治疗后,观察组的总缓解率为91.67%高于对照组的总缓解率(72.92%,P<0.05)。治疗后,2组血清4-1BBmRNA、4-1BBLmRNA、IgA、IgG、TNF-水平较治疗前降低,观察组低于对照组(P<0.05)。治疗后,观察组血清IL-10水平较治疗前升高,对照组IgM水平较治疗前降低,观察组血清IgM、IL-10水平均高于对照组(P<0.05)。治疗期间,2组不良反应比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上,雷公藤多苷对紫癜性肾炎患儿治疗效果较好,可有效降低单核细胞共刺激分子4-1 BB/4-1 BBL水平,迅速改善临床症状,安全性也较高。
Objective:To explore the efficacy and safety of tripterygium wilfordii polyglycoside in the treatment of child patients with purpura nephritis.Methods:A total of 96 child patients with purpura nephritis admitted to the pediatric department in our hospital were randomly divided into 2 groups,an experimental group and a control group with 48 cases in each group.The control group received routine treatment.The experimental group was treated with tripterygium wilfordii polyglycoside tablets,1 mg/(kg·d),3 times after meals on the basis of the control group.Both groups of children were treated continuously for 5 days.The clinical efficacy,4-1 BB/4-1 BBL,immune function,inflammatory factors and safety of the 2 groups were compared.Results:After treatment,the total remission rate of the experimental group was 91.67%higher than that of the control group(72.92%,P<0.05).After treatment,the serum levels of 4-1BBmRNA,4-1BBLmRNA,IgA,IgG,and TNF-in the 2 groups were lower than those before treatment,and the test group was lower than the control group(P<0.05).After treatment,the serum IL-10 level of the test group was higher than that before the treatment,and the IgM level of the control group was lower than that before the treatment.The serum IgM and IL-10 levels of the test group were higher than those of the control group(P<0.05).During the treatment period,there was no statistically significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion:On the basis of conventional treatment,tripterygium wilfordii polyglycoside has better therapeutic effect on child patients with purpuric nephritis,can effectively reduce the level of monocyte costimulatory molecule 4-1 BB/4-1 BBL,rapidly improve clinical symptoms,and has higher safety.
作者
何传梅
刘锦秀
韩红
伏广浩
刘晓东
周红亮
李慧
HE Chuanmei;LIU Jinxiu;HAN Hong;FU Guanghao;LIU Xiaodong;ZHOU Hongliang;LI Hui(The Second People′s Hospital of Lianyungang,Lianyungang 222000,China)
出处
《世界中医药》
CAS
2020年第20期3094-3096,共3页
World Chinese Medicine
基金
江苏省卫生计生委科研项目(LGY2017052)。
